Gilead Sciences

Merck and Gilead report mixed outcomes in lung cancer and HIV studies

HIV · 6 min

Merck Gilead report mixed outcomes in key lung cancer and HIV studies: a Phase 3 Trodelvy plus KEYTRUDA lung cancer trial was halted, while two Phase 3 HIV studies for islatravir/lenacapavir reported positive topline results. This plan focuses on the business and clinical implications for analysts and BD teams.

KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)

3 min

This page should frame the KRX English IR reference as a company disclosure/investor-relations document and give readers a concise way to navigate its purpose and likely themes. Keep the summary factual and avoid adding performance or product claims not present in the source.

Lenacapavir posts 100% HIV prevention in PURPOSE 1

FDA · HIV · 8 min

Gilead’s lenacapavir posted 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the case for Lenacapavir PrEP and raises the stakes for Gilead’s next regulatory and clinical catalysts.

Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials

oncology · 7 min

Gilead’s lenacapavir PrEP has emerged as a high-efficacy HIV prevention asset after Phase 3 results showed strong protection versus comparators. This plan focuses on what changed, why it matters for investors and BD teams, and the next catalysts to watch.

Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition

FDA · hepatitis · 9 min

Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.

Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis

FDA · cancer · 7 min

Eli Lilly and Gilead Sciences are at the forefront of a significant surge in pharmaceutical M&A activity, signaling a strategic shift towards targeted innovation. This analysis explores the drivers and implications of this trend for industry stakeholders.

ESMO 2025 Preview: Astra and Daiichi vs. Gilead

oncology · 3 min

As ESMO 2025 approaches, Astra and Daiichi are positioning themselves against Gilead. This article analyzes the implications for investors and pharma teams.

Gilead's Hepcludex Secures FDA Approval: Implications for Pharma

FDA · hepatitis · 3 min

Gilead Sciences' Hepcludex has received FDA approval for hepatitis D, marking a significant milestone after previous manufacturing setbacks. This article explores the implications for the pharmaceutical industry.

AstraZeneca and Daiichi Secure FDA Approval for Datroway in TNBC

FDA · TNBC · 3 min

AstraZeneca and Daiichi have gained FDA approval for Datroway as a first-line treatment for TNBC, surpassing Gilead. This article explores the implications for the pharmaceutical landscape.

FDA Approves Gilead's Hepatitis D Drug: Implications for Pharma

FDA · hepatitis · 2 min

The FDA has cleared Gilead's hepatitis D drug after a four-year wait, marking a significant milestone in hepatitis treatment. This article explores the implications for the pharmaceutical landscape.

Ibrance Heirs and Gilead's Tubulis Data at ASCO26

3 min

This article delves into the latest developments from ASCO26, focusing on Ibrance heirs and Gilead's Tubulis data. Discover the implications for pharmaceutical stakeholders.

Gilead's Commitment to Combat Visceral Leishmaniasis with AmBiosome

WHO · visceral leishmaniasis · 3 min

Gilead Sciences has pledged 400,000 doses of AmBiosome to fight visceral leishmaniasis in partnership with the WHO. This initiative marks a significant step in addressing this neglected tropical disease.